Charles Flexner is an expert on the basic and clinical pharmacology of drugs for HIV/AIDS and related infections, including viral hepatitis and tuberculosis. His current research includes the discovery and development of new molecules and formulations for long-acting parenteral administration for treatment and prevention of HIV infection. Dr. Flexner is the Deputy Director of the Institute for Clinical and Translational Research at Johns Hopkins, and Co-Principal Investigator of the Johns Hopkins University Baltimore-Washington-India Clinical Trials Unit. He currently serves as a consultant to the Bill and Melinda Gates Foundation and the Clinton Health Access Initiative, and served as a consultant on FDA reform to the United States House of Representatives.
At the completion of this educational session, learners will:
- Understand the potential for clinically significant drug-drug interactions involving the most recently approved HCV direct acting agents.
- Appreciate differences in the drug interaction potential of ledipasivir and velpatasvir.
- Know readily available resources for managing and avoiding HCV DAA drug interactions.
This CME activity was approved for AMA PRA Category 1 Credit™
on December 13, 2016 and will terminate December 12, 2019.
The target audience is all physicians, NPs and PAs involved or interested in HIV education.
This online video and post-activity evaluation are one hour in length.
After you complete the video portion of this educational activity there will be a post-activity evaluation and quiz.
You must achieve at least 70% correct to receive your CME certificate.
If successful, you will be provided instructions to print your CME certificate at the completion of this activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.
The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™
. Physicians should claim only the credit commensurate with extent of their participation in the activity.
Policies and standards of MSSNY require that speakers and planners for CME activities disclose any relevant financial relationships they may have with commercial interests whose products, devices or services may be discussed in the content of a CME activity.
Dr. James Braun (Planner/Course Director) had no relevant financial relationships to disclose.
Dr. Flexner (Presenter) has had the following personal financial relationships in the past 12 months with manufacturers of the products or services that may be presented in this CME activity: Consultant with Merck, and ViiV; research grant from Gilead. Dr. Flexner submitted his slides in advance for adequate peer review, and will support his presentation and clinical recommendations with the best available evidence from the medical literature.
This PRN CME activity is funded in part by unrestricted educational grants from:
Bristol-Myers Squibb, Gilead Sciences, Merck & Co, and ViiV Healthcare.
To obtain CME credit for this PRN program, please visit the PRN Courses Page
at the Clinical Education Initiative (CEI) web site. PRN and the Medical Society of the State of New York (MSSNY) jointly sponsor PRN enduring materials for CME, and provide them at no cost to the AIDS Institute of the New York State Department of Health (NYSDOH) for broadcast through the CEI. We thank the NYSDOH for making our CME programs available to a wider audience, and hope you will also browse the many other educational opportunities offered by the CEI.